Companies Ionis Pharmaceuticals Inc
Ionis Pharmaceuticals (IONS): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Ionis Pharmaceuticals Inc’s executive pay brief as a PDF
You get it on this page the moment you ask; press Download and a copy goes to your email too. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers40th pct.Of 20 peer CEOs
CEO pay, last three years
- $12,500,023FY2023
- $15,400,343FY2024
- $13,350,777FY2025
CEO total pay was $13,350,777 in fiscal 2025, down from $15,400,343 in fiscal 2024.
FY2025: salary $1,051,776 · bonus $2,398,049 · stock awards $8,444,838 · option awards $1,438,105
Executives and directors
Brett Monia · CEORichard Geary · ExecutiveBrian Birchler · EVPPatrick O'Neil · General CounselElizabeth Hougen · CFOEric Swayze · EVPAllene M. Diaz · Independent DirectorB. Lynne Parshall · Former director (through FY2025)Joan E. Herman · Independent DirectorJoseph H. Wender · Former director (through FY2025)Joseph Klein III · Independent DirectorJoseph Loscalzo · Chair of the BoardMichael Hayden · Independent DirectorMichael Yang · Independent DirectorSpencer R. Berthelsen · Independent Director
Frequently asked questions
Who was the highest-paid executive at Ionis Pharmaceuticals Inc in fiscal 2025?
As disclosed, Brett Monia (Chief Executive Officer) was the highest-paid executive at Ionis Pharmaceuticals Inc in fiscal 2025, with total compensation of $13,350,777.
How does Ionis Pharmaceuticals Inc's chief executive pay compare to its disclosed peer group?
As disclosed, Brett Monia's total compensation ranked at the 40th percentile of Ionis Pharmaceuticals Inc's disclosed peer group.
What is Ionis Pharmaceuticals Inc's CEO-to-median employee pay ratio?
As disclosed, Ionis Pharmaceuticals Inc's CEO-to-median employee pay ratio was 44:1.
How did shareholders vote on Ionis Pharmaceuticals Inc's executive compensation?
As disclosed, 96.38% of shareholders supported Ionis Pharmaceuticals Inc's executive compensation in the latest say-on-pay vote.
How much does Ionis Pharmaceuticals Inc spend in total on board compensation for fiscal 2025?
As disclosed, Ionis Pharmaceuticals Inc reported total board compensation of $2,756,383 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Brett Monia | $1,051,776 | $2,398,049 | $8,444,838 | $1,438,105 | $0 | $0 | $18,009 | $13,350,777 |
| Chief Executive Officer | ||||||||
| Elizabeth Hougen | 729,750 | 831,915 | 2,300,820 | 516,808 | 0 | 0 | 43,009 | 4,422,302 |
| EVP, Finance and Chief Financial Officer | ||||||||
| Richard Geary | 622,074 | 661,887 | 1,632,840 | 366,767 | 0 | 0 | 47,831 | 3,331,400 |
| EVP, Chief Development Officer | ||||||||
| Brian Birchler | 580,154 | 617,284 | 1,632,840 | 366,767 | 0 | 0 | 48,009 | 3,245,054 |
| EVP, Corporate and Development Operations | ||||||||
| Eric Swayze | 589,013 | 626,710 | 1,632,840 | 366,767 | 0 | 0 | 18,009 | 3,233,339 |
| EVP, Research | ||||||||
| Patrick O'Neil | 611,791 | 581,201 | 1,632,840 | 366,767 | 0 | 0 | 18,009 | 3,210,608 |
| EVP, Chief Legal Officer and General Counsel | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Brett Monia | $13,350,777 | $15,400,343 | $12,500,023 | ↓ −2,049,566 |
| Elizabeth Hougen | 4,422,302 | 5,062,061 | 2,891,527 | ↓ −639,759 |
| Richard Geary | 3,331,400 | 3,472,148 | 2,559,293 | ↓ −140,748 |
| Brian Birchler | 3,245,054 | 3,340,527 | 2,440,819 | ↓ −95,473 |
| Eric Swayze | 3,233,339 | 3,425,772 | 2,558,065 | ↓ −192,433 |
| Patrick O'Neil | 3,210,608 | 3,431,278 | 2,547,741 | ↓ −220,670 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Ionis designs its compensation structure to drive the creation of long-term stockholder value and mitigate unnecessary or imprudent business risk taking by using a balanced mix of fixed and variable cash incentives and long-term stock incentives. The company ties a significant portion of executive compensation to Company performance, ensuring that at-risk cash awards and performance-based equity are not guaranteed and can be zero if performance targets are not met.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Elizabeth Hougen | RSU | 2025-01-15 | — | — | 46,500 | — | $1,544,265 |
| Brett Monia | RSU | 2025-01-15 | — | — | 129,395 | — | 4,297,208 |
| Elizabeth Hougen | PSU | 2025-01-15 | 7,750 | 15,500 | — | 31,000 | 756,555 |
| Richard Geary | PSU | 2025-01-15 | 5,500 | 11,000 | — | 22,000 | 536,910 |
| Richard Geary | OPTION | 2025-01-02 | — | — | 22,000 | — | 366,767 |
| Patrick O'Neil | PSU | 2025-01-15 | 5,500 | 11,000 | — | 22,000 | 536,910 |
| Brian Birchler | PSU | 2025-01-15 | 5,500 | 11,000 | — | 22,000 | 536,910 |
| Eric Swayze | RSU | 2025-01-15 | — | — | 33,000 | — | 1,095,930 |
| Eric Swayze | PSU | 2025-01-15 | 5,500 | 11,000 | — | 22,000 | 536,910 |
| Patrick O'Neil | RSU | 2025-01-15 | — | — | 33,000 | — | 1,095,930 |
| Brian Birchler | RSU | 2025-01-15 | — | — | 33,000 | — | 1,095,930 |
| Brett Monia | PSU | 2025-01-15 | 42,488 | 84,975 | — | 169,950 | 4,147,630 |
| Richard Geary | RSU | 2025-01-15 | — | — | 33,000 | — | 1,095,930 |
| Patrick O'Neil | OPTION | 2025-01-02 | — | — | 22,000 | — | 366,767 |
| Brett Monia | OPTION | 2025-01-02 | — | — | 86,263 | — | 1,438,105 |
| Eric Swayze | OPTION | 2025-01-02 | — | — | 22,000 | — | 366,767 |
| Brian Birchler | OPTION | 2025-01-02 | — | — | 22,000 | — | 366,767 |
| Elizabeth Hougen | OPTION | 2025-01-02 | — | — | 31,000 | — | 516,808 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Elizabeth Hougen | $1,544,265 | $756,555 | $516,808 | 26.9% |
| Brett Monia | 4,297,208 | 4,147,630 | 1,438,105 | 42.0% |
| Richard Geary | 1,095,930 | 536,910 | 366,767 | 26.9% |
| Patrick O'Neil | 1,095,930 | 536,910 | 366,767 | 26.9% |
| Brian Birchler | 1,095,930 | 536,910 | 366,767 | 26.9% |
| Eric Swayze | 1,095,930 | 536,910 | 366,767 | 26.9% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Brian Birchler | Option | 407 | 32.6 | — |
| Eric Swayze | Option | 620 | 32.6 | — |
| Richard Geary | Option | 637 | 32.6 | — |
| Patrick O'Neil | Option | 637 | 32.6 | — |
| Elizabeth Hougen | Option | 690 | 32.6 | — |
| Brian Birchler | Option | 938 | 35.25 | — |
| Brian Birchler | RSU | 1,875 | — | 148,331 |
| Brett Monia | Option | 2,115 | 32.6 | — |
| Brian Birchler | RSU | 2,437 | — | 192,791 |
| Eric Swayze | RSU | 3,714 | — | 293,815 |
| Richard Geary | RSU | 3,821 | — | 302,279 |
| Patrick O'Neil | RSU | 3,821 | — | 302,279 |
| Elizabeth Hougen | RSU | 4,139 | — | 327,436 |
| Richard Geary | RSU | 4,250 | — | 336,218 |
| Brian Birchler | RSU | 4,250 | — | 336,218 |
| Eric Swayze | RSU | 4,250 | — | 336,218 |
| Patrick O'Neil | RSU | 4,250 | — | 336,218 |
| Richard Geary | RSU | 5,500 | — | 435,105 |
| Brian Birchler | RSU | 5,500 | — | 435,105 |
| Eric Swayze | RSU | 5,500 | — | 435,105 |
| Patrick O'Neil | RSU | 5,500 | — | 435,105 |
| Richard Geary | Option | 6,213 | 37.58 | — |
| Brian Birchler | Option | 6,213 | 37.58 | — |
| Eric Swayze | Option | 6,213 | 37.58 | — |
| Patrick O'Neil | Option | 6,213 | 37.58 | — |
| Elizabeth Hougen | RSU | 6,750 | — | 533,993 |
| Elizabeth Hougen | Option | 7,027 | 37.58 | — |
| Elizabeth Hougen | RSU | 7,750 | — | 613,103 |
| Richard Geary | RSU | 8,603 | — | 680,583 |
| Brian Birchler | RSU | 8,603 | — | 680,583 |
| Eric Swayze | RSU | 8,603 | — | 680,583 |
| Patrick O'Neil | RSU | 8,603 | — | 680,583 |
| Elizabeth Hougen | RSU | 9,730 | — | 769,740 |
| Richard Geary | RSU | 11,991 | — | 948,608 |
| Brian Birchler | RSU | 11,991 | — | 948,608 |
| Eric Swayze | RSU | 11,991 | — | 948,608 |
| Patrick O'Neil | RSU | 11,991 | — | 948,608 |
| Brett Monia | RSU | 12,686 | — | 1,003,589 |
| Elizabeth Hougen | RSU | 13,562 | — | 1,072,890 |
| Richard Geary | Option | 14,167 | 52.87 | — |
| Brian Birchler | Option | 14,167 | 52.87 | — |
| Eric Swayze | Option | 14,167 | 52.87 | — |
| Patrick O'Neil | Option | 14,167 | 52.87 | — |
| Richard Geary | RSU | 15,300 | — | 1,210,383 |
| Brian Birchler | RSU | 15,300 | — | 1,210,383 |
| Eric Swayze | RSU | 15,300 | — | 1,210,383 |
| Patrick O'Neil | RSU | 15,300 | — | 1,210,383 |
| Richard Geary | Option | 22,000 | 34.69 | — |
| Brian Birchler | Option | 22,000 | 34.69 | — |
| Eric Swayze | Option | 22,000 | 34.69 | — |
| Patrick O'Neil | Option | 22,000 | 34.69 | — |
| Elizabeth Hougen | Option | 22,500 | 52.87 | — |
| Elizabeth Hougen | RSU | 24,300 | — | 1,922,373 |
| Elizabeth Hougen | Option | 31,000 | 34.69 | — |
| Brett Monia | Option | 32,141 | 37.58 | — |
| Richard Geary | RSU | 33,000 | — | 2,610,630 |
| Brian Birchler | RSU | 33,000 | — | 2,610,630 |
| Eric Swayze | RSU | 33,000 | — | 2,610,630 |
| Patrick O'Neil | RSU | 33,000 | — | 2,610,630 |
| Brett Monia | RSU | 35,887 | — | 2,839,021 |
| Brett Monia | RSU | 42,487 | — | 3,361,147 |
| Brett Monia | RSU | 44,502 | — | 3,520,553 |
| Elizabeth Hougen | RSU | 46,500 | — | 3,678,615 |
| Brett Monia | Option | 60,719 | 52.87 | — |
| Brett Monia | RSU | 65,576 | — | 5,187,717 |
| Brett Monia | Option | 86,263 | 34.69 | — |
| Brett Monia | RSU | 122,214 | — | 9,668,350 |
| Brett Monia | RSU | 129,395 | — | 10,236,438 |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Joseph H. WenderIndependent · Compensation · Finance (Chair) · Nominating, Governance and Review (Chair) · Not standing for re-election · Partial-year service | $150,000 | $208,487 | $240,293 | — | $0 | $598,780 |
| Joseph LoscalzoIndependent · Nominating, Governance and Review · Medical and Science** · Partial-year service | 120,000 | 208,487 | 240,293 | — | 0 | 568,780 |
| Spencer R. BerthelsenIndependent · Compensation (Chair) · Nominating, Governance and Review · Medical and Science** · Partial-year service | 100,000 | 208,487 | 240,293 | — | 0 | 548,780 |
| Joseph Klein IIIIndependent · Finance | 95,000 | 208,487 | 240,293 | — | 0 | 543,780 |
| Joan E. HermanIndependent · Audit · Compensation · Compliance · Partial-year service | 92,500 | 208,487 | 240,293 | — | 0 | 541,280 |
| B. Lynne ParshallIndependent · Compliance (Chair) · Finance · Not standing for re-election · Partial-year service | 90,000 | 208,487 | 240,293 | — | 0 | 538,780 |
| Allene M. DiazIndependent · Audit · Compliance · Partial-year service | 82,500 | 208,487 | 240,293 | — | 0 | 531,280 |
| Michael HaydenIndependent · Medical and Science** (Chair) · Partial-year service | 80,000 | 208,487 | 240,293 | — | 0 | 528,780 |
| Michael YangIndependent · Compliance · Partial-year service | 70,000 | 208,487 | 240,293 | — | 0 | 518,780 |
| Brett P. MoniaEmployee director | — | — | — | — | — | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $60,000 |
|---|---|
| Annual equity retainer | $450,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 25,000 / 20,000 / 20,000 |
| Stock ownership guideline | $5 |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $880,000 |
| Equity awards (grant-date value) | $1,876,383 |
| All other compensation | $0 |
| Total cost of the board | $2,756,383 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Ionis Pharmaceuticals as a peer
Companies that benchmark against IONS
39 companies name IONS as a compensation peer
The list of companies that name IONS as a peer is temporarily unavailable — recheck shortly.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
BCRX BioCryst Pharmaceuticals, Inc.ACAD Acadia PharmaceuticalsALKS AlkermesFOLD Amicus TherapeuticsAPLS Apellis PharmaceuticalsAXSM Axsome Therapeutics, Inc.BMRN BioMarin PharmaceuticalsCORT Corcept Therapeutics Inc.EXAS Exact Sciences CorpEXEL ExelixisHALO Halozyme TherapeuticsJAZZ Jazz PharmaceuticalsPTCT PTC TherapeuticsSRPT Sarepta TherapeuticsRARE Ultragenyx PharmaceuticalUTHR United TherapeuticsNBIX Neurocrine BiosciencesINCY Incyte CorporationBPMC Blueprint Medicines CorpINSM Insmed
Peer reciprocity
The companies Ionis Pharmaceuticals Inc names as compensation peers that name it back in their own disclosed peer groups.
Acadia Pharmaceuticals (ACAD)169Amicus Therapeutics (FOLD)170Apellis Pharmaceuticals (APLS)171BioMarin Pharmaceuticals (BMRN)172Exelixis (EXEL)173Halozyme Therapeutics (HALO)174PTC Therapeutics (PTCT)175Sarepta Therapeutics (SRPT)176Ultragenyx Pharmaceutical (RARE)177United Therapeutics (UTHR)178Neurocrine Biosciences (NBIX)179Incyte Corporation (INCY)180Blueprint Medicines Corp (BPMC)181Insmed (INSM)182
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Exelixis | 2025 | Michael Morrissey | $1,306,040 | $30,539,552 | $0 | $1,382,591 | $33,239,183 |
| 2 | Incyte Corporation | 2025 | William Meury | 647,260 | 27,509,657 | 2,573,998 | 1,300,000 | 32,085,952 |
| 3 | PTC Therapeutics | 2025 | Matthew Klein | 958,500 | 16,593,800 | 4,399,760 | 1,294,000 | 23,266,326 |
| 4 | Halozyme Therapeutics | 2025 | Helen Torley | 1,000,000 | 19,350,145 | 1,650,014 | 1,147,500 | 23,166,223 |
| 5 | BioMarin Pharmaceuticals | 2025 | Alexander Hardy | 1,130,769 | 16,833,629 | 1,909,310 | 1,644,500 | 21,927,563 |
| 6 | Jazz Pharmaceuticals | 2025 | Renee Gala | 1,003,269 | 16,138,433 | 0 | 1,980,000 | 19,151,558 |
| 7 | United Therapeutics | 2025 | Martine Rothblatt | 1,545,005 | 6,067,990 | 6,075,804 | 4,281,875 | 18,038,972 |
| 8 | Exact Sciences Corp | 2024 | Kevin Conroy | 1,083,368 | 13,496,138 | 0 | 712,329 | 15,539,378 |
| 9 | Corcept Therapeutics Inc. | 2025 | Joseph Belanoff | 1,182,333 | 0 | 12,907,718 | 0 | 15,303,551 |
| 10 | Insmed | 2025 | William Lewis | 854,550 | 2,999,940 | 9,000,033 | 1,495,463 | 14,467,393 |
| 11 | Blueprint Medicines Corp | 2024 | Kathryn Haviland | 821,363 | 7,472,480 | 4,315,144 | 854,217 | 13,477,004 |
| 12 | Neurocrine Biosciences | 2025 | Kyle Gano | 920,000 | 5,750,023 | 5,750,006 | 0 | 13,448,935 |
| 13 | Ionis Pharmaceuticals Inc | 2025 | Brett Monia | 1,051,776 | 8,444,838 | 1,438,105 | 0 | 13,350,777 |
| 14 | BioCryst Pharmaceuticals, Inc. | 2025 | Jon Stonehouse | 728,466 | 0 | 11,132,458 | 1,052,633 | 12,951,082 |
| 15 | Ultragenyx Pharmaceutical | 2025 | Emil Kakkis | 861,100 | 8,364,938 | 1,847,356 | 299,663 | 11,405,535 |
| 16 | Apellis Pharmaceuticals | 2024 | Cedric Francois | 793,193 | 4,779,832 | 4,787,768 | 0 | 10,957,451 |
| 17 | Axsome Therapeutics, Inc. | 2025 | Herriot Tabuteau | 835,000 | 5,533,554 | 2,833,237 | 876,750 | 10,283,492 |
| 18 | Amicus Therapeutics | 2024 | Bradley Campbell | 767,308 | 4,990,365 | 2,105,627 | 0 | 8,526,943 |
| 19 | Acadia Pharmaceuticals | 2025 | Catherine Owen Adams | 930,000 | 3,240,558 | 3,234,797 | 818,559 | 8,256,518 |
| 20 | Alkermes | 2025 | Richard Pops | 1,250,769 | 0 | 5,020,812 | 1,626,000 | 7,915,081 |
| 21 | Sarepta Therapeutics | 2025 | Douglas Ingram | 1,171,425 | 6,000,005 | 0 | 649,000 | 7,840,666 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Ionis Pharmaceuticals Inc | not disclosed | PRSU 40 · Option 30 · RSU 30 | Yes — Relative TSR | Aon |
| Acadia Pharmaceuticals | 110% | Options 50 · PSU 25 · RSU 25 | Yes | Frederic W. Cook & Co., Inc. (FW Cook) |
| Alkermes | 130% | PRSU 53 · RSU 24 · Option 23 | Yes — Relative Total Shareholder Return (TSR) | Alpine Rewards LLC |
| Amicus Therapeutics | not disclosed | Option 33 · RSU 33 · PRSU 33 | Yes — TSR Goal | Pay Governance |
| Apellis Pharmaceuticals | 90.74% | RSU 50 · PSU 50 | not disclosed | Pay Governance |
| Axsome Therapeutics, Inc. | 150% | RSU 33 · Options 33 · PSU 33 | No | Frederic W. Cook & Co., Inc. |
| BioCryst Pharmaceuticals, Inc. | not disclosed | not disclosed | not disclosed | Aon |
| BioMarin Pharmaceuticals | 130% | PSU 66 · RSU 21 · Options 13 | Yes — Relative TSR | Aon Human Capital Solutions |
| Blueprint Medicines Corp | 130% | RSU 37 · Options 32 · PSU 31 | Yes — Relative Total Stockholder Return (rTSR) | Aon |
| Corcept Therapeutics Inc. | Dr. Belanoff: 100%; Dr. Guyer: 120%; Mr. Maduck: 80%; Mr. Mokari: 100%; Mr. Robb: 100%% | Stock Options 100 | not disclosed | not disclosed |
| Exact Sciences Corp | 47% | PSU 60 · RSU 40 | No | Aon |
| Exelixis | 105% | PSU 50 · RSU 50 | Yes — 2025 Relative TSR Goal | Aon |
| Halozyme Therapeutics | 127.5% | PSU 50 · RSU 35 · Option 15 | No | F.W. Cook & Co., Inc. |
| Incyte Corporation | 138.6% | PSU 60 · RSU 20 · Option 20 | Yes — relative total shareholder return (TSR) | Aon |
| Insmed | 175% | Options 75 · RSU 25 | No | Willis Towers Watson (WTW) |
| Jazz Pharmaceuticals | 150% | RSU 50 · PSU 50 | Yes — Relative TSR | Aon |
| Neurocrine Biosciences | 105% | Option 50 · PRSU 30 · RSU 20 | No | Frederic W. Cook & Co., Inc. |
| PTC Therapeutics | not disclosed | Option 50 · RSU 50 | Yes — TSR relative to Nasdaq Biotechnology Index | Frederic W. Cook & Co., Inc. |
| Sarepta Therapeutics | 100% | PSU 50 · Option 25 · RSU 25 | No | FW Cook |
| Ultragenyx Pharmaceutical | 44% | PSU 60 · RSU 20 · Options 20 | Yes — Relative TSR | Aon's Human Capital Solutions Practice |
| United Therapeutics | 221% | PSO 50 · PSU 50 | No | Aon |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-04 | 135,537,973 | 5,088,105 | 112,937 | 96.38% | Passed |
| 2025 | 2025-06-05 | 132,567,606 | 5,738,006 | 104,590 | 95.78% | Passed |
| 2024 | 2024-06-06 | 118,899,475 | 4,228,901 | 341,740 | 96.57% | Passed |
| 2023 | 2023-06-01 | 117,265,241 | 2,746,636 | 100,148 | 97.63% | Passed |
| 2022 | 2022-06-02 | 97,212,084 | 16,817,773 | 117,270 | 85.16% | Passed |
| 2021 | 2021-06-02 | 103,175,839 | 11,890,249 | 209,706 | 89.67% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-04 | 96.38%a |
| 2025 | 2025-06-05 | 95.78%b |
| 2024 | 2024-06-06 | 96.57%c |
a. Approved under the standard stated in the filing — “Abstentions will have no effect on Proposals 1, 3, and 4.”.
b. Approved under the standard stated in the filing — “Abstentions and broker non-votes, if any, will have no effect.”.
c. Approved under the standard stated in the filing — “Abstentions will have no effect on Proposal 1 and Proposal 3.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 44 : 1 |
|---|---|
| CEO total compensation | $13,350,777 |
| Median employee compensation | $304,680 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Joseph Baroldi | EVP, Chief Business Officer | 2026-04-28 | D | 1,626 | $72 | $116,727 | Common | Form 4 ↗ |
| Joseph Klein III | Director | 2026-05-01 | D | 10,111 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Joseph Klein III | Director | 2026-05-01 | A | 10,111 | 47 | 476,329 | Common | Form 4 ↗ |
| Joseph Klein III | Director | 2026-05-01 | D | 8,680 | 73 | 636,704 | Common | Form 4 ↗ |
| Joseph Klein III | Director | 2026-05-01 | D | 1,431 | 74 | 106,534 | Common | Form 4 ↗ |
| Joseph Loscalzo | Director | 2026-05-04 | D | 16,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Joseph Loscalzo | Director | 2026-05-04 | D | 16,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Joseph Loscalzo | Director | 2026-05-04 | D | 10,321 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Joseph Loscalzo | Director | 2026-05-04 | A | 12,000 | 60 | 722,400 | Common | Form 4 ↗ |
| Joseph Loscalzo | Director | 2026-05-04 | A | 10,968 | 38 | 417,442 | Common | Form 4 ↗ |
| Joseph Loscalzo | Director | 2026-05-04 | A | 16,000 | 65 | 1,036,800 | Common | Form 4 ↗ |
| Joseph Loscalzo | Director | 2026-05-04 | D | 10,968 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Joseph Loscalzo | Director | 2026-05-04 | A | 12,000 | 40 | 480,600 | Common | Form 4 ↗ |
| Joseph Loscalzo | Director | 2026-05-04 | D | 12,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Joseph Loscalzo | Director | 2026-05-04 | D | 12,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Joseph Loscalzo | Director | 2026-05-04 | D | 17,781 | 76 | 1,343,934 | Common | Form 4 ↗ |
| Joseph Loscalzo | Director | 2026-05-04 | D | 59,508 | 75 | 4,457,292 | Common | Form 4 ↗ |
| Joseph Loscalzo | Director | 2026-05-04 | A | 16,000 | 43 | 686,080 | Common | Form 4 ↗ |
| Joseph Loscalzo | Director | 2026-05-04 | A | 10,321 | 41 | 423,987 | Common | Form 4 ↗ |
| Brett P. Monia | Director | 2026-05-13 | A | 1,316 | 33 | 42,902 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-05-13 | — | 1,316 | — | — | 1 insider, 1 accrual row | ||
| Brett P. Monia | Director | 2026-05-13 | D | 1,316 | 78 | 102,665 | Common | Form 4 ↗ |
| Brett P. Monia | Director | 2026-05-14 | D | 3,220 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brett P. Monia | Director | 2026-05-14 | D | 3,220 | 79 | 253,347 | Common | Form 4 ↗ |
| Brett P. Monia | Director | 2026-05-14 | A | 3,220 | 33 | 104,972 | Common | Form 4 ↗ |
| Spencer R. Berthelsen | Director | 2026-06-01 | A | 8,000 | 24 | 195,360 | Common | Form 4 ↗ |
| Spencer R. Berthelsen | Director | 2026-06-01 | D | 8,000 | 76 | 605,360 | Common | Form 4 ↗ |
| Spencer R. Berthelsen | Director | 2026-06-01 | D | 8,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ludwig Hantson | Director | 2026-06-04 | A | 10,753 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Peter N. Reikes | Director | 2026-06-04 | A | 10,753 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Holly B. Kordasiewicz | EVP, Chief Development Officer | 2026-06-12 | A | 12,000 | 33 | 391,200 | Common | Form 4 ↗ |
| Holly B. Kordasiewicz | EVP, Chief Development Officer | 2026-06-12 | D | 7,951 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Holly B. Kordasiewicz | EVP, Chief Development Officer | 2026-06-12 | D | 12,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Holly B. Kordasiewicz | EVP, Chief Development Officer | 2026-06-12 | D | 41,004 | 73 | 2,997,122 | Common | Form 4 ↗ |
| Holly B. Kordasiewicz | EVP, Chief Development Officer | 2026-06-12 | A | 19,895 | 57 | 1,129,638 | Common | Form 4 ↗ |
| Holly B. Kordasiewicz | EVP, Chief Development Officer | 2026-06-12 | A | 7,951 | 61 | 484,136 | Common | Form 4 ↗ |
| Holly B. Kordasiewicz | EVP, Chief Development Officer | 2026-06-12 | D | 21,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Holly B. Kordasiewicz | EVP, Chief Development Officer | 2026-06-12 | A | 21,000 | 61 | 1,278,690 | Common | Form 4 ↗ |
| Holly B. Kordasiewicz | EVP, Chief Development Officer | 2026-06-12 | D | 19,842 | 74 | 1,469,306 | Common | Form 4 ↗ |
| Holly B. Kordasiewicz | EVP, Chief Development Officer | 2026-06-12 | D | 19,895 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Spencer R. Berthelsen | Director | 2026-06-15 | D | 8,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Spencer R. Berthelsen | Director | 2026-06-15 | D | 8,000 | 73 | 587,920 | Common | Form 4 ↗ |
| Spencer R. Berthelsen | Director | 2026-06-15 | A | 8,000 | 24 | 195,360 | Common | Form 4 ↗ |
| Brett P. Monia | Director | 2026-06-24 | D | 14,565 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brett P. Monia | Director | 2026-06-24 | D | 14,565 | 78 | 1,142,082 | Common | Form 4 ↗ |
| Brett P. Monia | Director | 2026-06-24 | A | 14,565 | 33 | 474,819 | Common | Form 4 ↗ |
| Brett P. Monia | Director | 2026-06-25 | D | 21,072 | 78 | 1,653,941 | Common | Form 4 ↗ |
| Eric Swayze | EVP Research | 2026-06-25 | D | 10,602 | 79 | 839,492 | Common | Form 4 ↗ |
| Brett P. Monia | Director | 2026-06-25 | D | 21,072 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brett P. Monia | Director | 2026-06-25 | A | 21,072 | 33 | 686,947 | Common | Form 4 ↗ |
| Joseph Baroldi | EVP, Chief Business Officer | 2026-06-26 | D | 3,866 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brett P. Monia | Director | 2026-06-26 | D | 50,000 | 81 | 4,029,500 | Common | Form 4 ↗ |
| Brett P. Monia | Director | 2026-06-26 | D | 50,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brett P. Monia | Director | 2026-06-26 | A | 50,000 | 57 | 2,839,000 | Common | Form 4 ↗ |
| Eugene Schneider | EVP, Chf Clinical Develop Ofcr | 2026-06-26 | D | 26,000 | 81 | 2,107,196 | Common | Form 4 ↗ |
| Eugene Schneider | EVP, Chf Clinical Develop Ofcr | 2026-06-26 | A | 26,000 | 61 | 1,583,140 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-06-26 | — | 1,769 | — | — | 1 insider, 1 accrual row | ||
| Joseph Baroldi | EVP, Chief Business Officer | 2026-06-26 | D | 5,635 | 80 | 451,699 | Common | Form 4 ↗ |
| Eugene Schneider | EVP, Chf Clinical Develop Ofcr | 2026-06-26 | D | 26,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Joseph Baroldi | EVP, Chief Business Officer | 2026-06-26 | A | 1,769 | 33 | 57,669 | Common | Form 4 ↗ |
| Joseph Baroldi | EVP, Chief Business Officer | 2026-06-26 | A | 3,866 | 57 | 219,511 | Common | Form 4 ↗ |
| Patrick O'Neil | EVP CLO & General Counsel | 2026-06-26 | D | 3,069 | 80 | 245,520 | Common | Form 4 ↗ |
| Allene M. Diaz | Director | 2026-07-01 | A | 2,301 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Spencer R. Berthelsen | Director | 2026-07-01 | A | 5,369 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Allene M. Diaz | Director | 2026-07-01 | A | 5,369 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Hayden | Director | 2026-07-01 | A | 2,301 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Hayden | Director | 2026-07-01 | A | 5,369 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Joseph Klein III | Director | 2026-07-01 | D | 99 | 79 | 7,866 | Common | Form 4 ↗ |
| Joan E. Herman | Director | 2026-07-01 | A | 5,369 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Joseph Klein III | Director | 2026-07-01 | A | 11,518 | 40 | 460,029 | Common | Form 4 ↗ |
| Michael Yang | Director | 2026-07-01 | A | 2,301 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Yang | Director | 2026-07-01 | A | 5,369 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Joseph Klein III | Director | 2026-07-01 | D | 11,419 | 79 | 902,551 | Common | Form 4 ↗ |
| Joseph Klein III | Director | 2026-07-01 | D | 11,518 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Joan E. Herman | Director | 2026-07-01 | A | 2,301 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Joseph Loscalzo | Director | 2026-07-01 | A | 2,301 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Joseph Klein III | Director | 2026-07-01 | A | 2,301 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Joseph Klein III | Director | 2026-07-01 | A | 5,369 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Spencer R. Berthelsen | Director | 2026-07-01 | A | 2,301 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Joseph Loscalzo | Director | 2026-07-01 | A | 5,369 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Allene M. Diaz | Director | 2026-07-07 | D | 10,111 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Allene M. Diaz | Director | 2026-07-07 | D | 10,111 | 85 | 863,637 | Common | Form 4 ↗ |
| C. Frank Bennett | EVP, Chief Scientific Officer | 2026-07-07 | D | 15,000 | 85 | 1,281,930 | Common | Form 4 ↗ |
| Allene M. Diaz | Director | 2026-07-07 | A | 10,111 | 47 | 476,329 | Common | Form 4 ↗ |
| C. Frank Bennett | EVP, Chief Scientific Officer | 2026-07-07 | D | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| C. Frank Bennett | EVP, Chief Scientific Officer | 2026-07-07 | D | 5,536 | 84 | 462,693 | Common | Form 4 ↗ |
| C. Frank Bennett | EVP, Chief Scientific Officer | 2026-07-07 | A | 15,000 | 0 | 0 | Common | Form 4 ↗ |
| Holly B. Kordasiewicz | EVP, Chief Development Officer | 2026-07-07 | D | 362 | 84 | 30,517 | Common | Form 4 ↗ |
| Spencer R. Berthelsen | Director | 2026-07-15 | D | 5,220 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Spencer R. Berthelsen | Director | 2026-07-15 | A | 5,220 | 0 | 0 | Common | Form 4 ↗ |
| Joan E. Herman | Director | 2026-07-15 | D | 5,220 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Joan E. Herman | Director | 2026-07-15 | A | 5,220 | 0 | 0 | Common | Form 4 ↗ |
| Peter N. Reikes | Director | 2026-07-15 | A | 3,399 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ludwig Hantson | Director | 2026-07-15 | A | 3,399 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Hayden | Director | 2026-07-30 | A | 15,000 | 53 | 800,700 | Common | Form 4 ↗ |
| Michael Hayden | Director | 2026-07-31 | A | 5,000 | 52 | 258,000 | Common | Form 4 ↗ |
| Brett P. Monia | Director | 2026-08-31 | A | 98 | 51 | 5,028 | Common | Form 4 ↗ |
| Brian Birchler | EVP, Corp and Development Ops | 2026-08-31 | A | 58 | 51 | 2,976 | Common | Form 4 ↗ |
| Patrick O'Neil | EVP CLO & General Counsel | 2026-08-31 | A | 63 | 51 | 3,232 | Common | Form 4 ↗ |
| C. Frank Bennett | EVP, Chief Scientific Officer | 2026-08-31 | A | 110 | 51 | 5,644 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-10-15 | — | 125 | — | — | 1 insider, 1 accrual row | ||
| Eric Swayze | EVP Research | 2026-10-15 | A | 125 | 0 | 0 | Common | Form 4 ↗ |
| Shannon L. Devers | EVP, Chief Human Resources Ofc | 2026-10-15 | D | 2,820 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Shannon L. Devers | EVP, Chief Human Resources Ofc | 2026-10-15 | A | 2,820 | 0 | 0 | Common | Form 4 ↗ |
| Eric Swayze | EVP Research | 2026-10-16 | D | 53 | 44 | 2,308 | Common | Form 4 ↗ |
| Shannon L. Devers | EVP, Chief Human Resources Ofc | 2026-10-16 | D | 1,357 | 44 | 59,082 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
View all 106 transactions
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Joseph Baroldi | EVP, Chief Business Officer | 2026-04-28 | D | 1,626 | $72 | $116,727 | Common | Form 4 ↗ |
| Joseph Klein III | Director | 2026-05-01 | D | 10,111 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Joseph Klein III | Director | 2026-05-01 | A | 10,111 | 47 | 476,329 | Common | Form 4 ↗ |
| Joseph Klein III | Director | 2026-05-01 | D | 8,680 | 73 | 636,704 | Common | Form 4 ↗ |
| Joseph Klein III | Director | 2026-05-01 | D | 1,431 | 74 | 106,534 | Common | Form 4 ↗ |
| Joseph Loscalzo | Director | 2026-05-04 | D | 16,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Joseph Loscalzo | Director | 2026-05-04 | D | 16,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Joseph Loscalzo | Director | 2026-05-04 | D | 10,321 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Joseph Loscalzo | Director | 2026-05-04 | A | 12,000 | 60 | 722,400 | Common | Form 4 ↗ |
| Joseph Loscalzo | Director | 2026-05-04 | A | 10,968 | 38 | 417,442 | Common | Form 4 ↗ |
| Joseph Loscalzo | Director | 2026-05-04 | A | 16,000 | 65 | 1,036,800 | Common | Form 4 ↗ |
| Joseph Loscalzo | Director | 2026-05-04 | D | 10,968 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Joseph Loscalzo | Director | 2026-05-04 | A | 12,000 | 40 | 480,600 | Common | Form 4 ↗ |
| Joseph Loscalzo | Director | 2026-05-04 | D | 12,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Joseph Loscalzo | Director | 2026-05-04 | D | 12,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Joseph Loscalzo | Director | 2026-05-04 | D | 17,781 | 76 | 1,343,934 | Common | Form 4 ↗ |
| Joseph Loscalzo | Director | 2026-05-04 | D | 59,508 | 75 | 4,457,292 | Common | Form 4 ↗ |
| Joseph Loscalzo | Director | 2026-05-04 | A | 16,000 | 43 | 686,080 | Common | Form 4 ↗ |
| Joseph Loscalzo | Director | 2026-05-04 | A | 10,321 | 41 | 423,987 | Common | Form 4 ↗ |
| Brett P. Monia | Director | 2026-05-13 | A | 1,316 | 33 | 42,902 | Common | Form 4 ↗ |
| Brett P. Monia | Director | 2026-05-13 | D | 1,316 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brett P. Monia | Director | 2026-05-13 | D | 1,316 | 78 | 102,665 | Common | Form 4 ↗ |
| Brett P. Monia | Director | 2026-05-14 | D | 3,220 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brett P. Monia | Director | 2026-05-14 | D | 3,220 | 79 | 253,347 | Common | Form 4 ↗ |
| Brett P. Monia | Director | 2026-05-14 | A | 3,220 | 33 | 104,972 | Common | Form 4 ↗ |
| Spencer R. Berthelsen | Director | 2026-06-01 | A | 8,000 | 24 | 195,360 | Common | Form 4 ↗ |
| Spencer R. Berthelsen | Director | 2026-06-01 | D | 8,000 | 76 | 605,360 | Common | Form 4 ↗ |
| Spencer R. Berthelsen | Director | 2026-06-01 | D | 8,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ludwig Hantson | Director | 2026-06-04 | A | 10,753 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Peter N. Reikes | Director | 2026-06-04 | A | 10,753 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Holly B. Kordasiewicz | EVP, Chief Development Officer | 2026-06-12 | A | 12,000 | 33 | 391,200 | Common | Form 4 ↗ |
| Holly B. Kordasiewicz | EVP, Chief Development Officer | 2026-06-12 | D | 7,951 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Holly B. Kordasiewicz | EVP, Chief Development Officer | 2026-06-12 | D | 12,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Holly B. Kordasiewicz | EVP, Chief Development Officer | 2026-06-12 | D | 41,004 | 73 | 2,997,122 | Common | Form 4 ↗ |
| Holly B. Kordasiewicz | EVP, Chief Development Officer | 2026-06-12 | A | 19,895 | 57 | 1,129,638 | Common | Form 4 ↗ |
| Holly B. Kordasiewicz | EVP, Chief Development Officer | 2026-06-12 | A | 7,951 | 61 | 484,136 | Common | Form 4 ↗ |
| Holly B. Kordasiewicz | EVP, Chief Development Officer | 2026-06-12 | D | 21,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Holly B. Kordasiewicz | EVP, Chief Development Officer | 2026-06-12 | A | 21,000 | 61 | 1,278,690 | Common | Form 4 ↗ |
| Holly B. Kordasiewicz | EVP, Chief Development Officer | 2026-06-12 | D | 19,842 | 74 | 1,469,306 | Common | Form 4 ↗ |
| Holly B. Kordasiewicz | EVP, Chief Development Officer | 2026-06-12 | D | 19,895 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Spencer R. Berthelsen | Director | 2026-06-15 | D | 8,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Spencer R. Berthelsen | Director | 2026-06-15 | D | 8,000 | 73 | 587,920 | Common | Form 4 ↗ |
| Spencer R. Berthelsen | Director | 2026-06-15 | A | 8,000 | 24 | 195,360 | Common | Form 4 ↗ |
| Brett P. Monia | Director | 2026-06-24 | D | 14,565 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brett P. Monia | Director | 2026-06-24 | D | 14,565 | 78 | 1,142,082 | Common | Form 4 ↗ |
| Brett P. Monia | Director | 2026-06-24 | A | 14,565 | 33 | 474,819 | Common | Form 4 ↗ |
| Brett P. Monia | Director | 2026-06-25 | D | 21,072 | 78 | 1,653,941 | Common | Form 4 ↗ |
| Eric Swayze | EVP Research | 2026-06-25 | D | 10,602 | 79 | 839,492 | Common | Form 4 ↗ |
| Brett P. Monia | Director | 2026-06-25 | D | 21,072 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brett P. Monia | Director | 2026-06-25 | A | 21,072 | 33 | 686,947 | Common | Form 4 ↗ |
| Joseph Baroldi | EVP, Chief Business Officer | 2026-06-26 | D | 3,866 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brett P. Monia | Director | 2026-06-26 | D | 50,000 | 81 | 4,029,500 | Common | Form 4 ↗ |
| Brett P. Monia | Director | 2026-06-26 | D | 50,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brett P. Monia | Director | 2026-06-26 | A | 50,000 | 57 | 2,839,000 | Common | Form 4 ↗ |
| Eugene Schneider | EVP, Chf Clinical Develop Ofcr | 2026-06-26 | D | 26,000 | 81 | 2,107,196 | Common | Form 4 ↗ |
| Eugene Schneider | EVP, Chf Clinical Develop Ofcr | 2026-06-26 | A | 26,000 | 61 | 1,583,140 | Common | Form 4 ↗ |
| Joseph Baroldi | EVP, Chief Business Officer | 2026-06-26 | D | 1,769 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Joseph Baroldi | EVP, Chief Business Officer | 2026-06-26 | D | 5,635 | 80 | 451,699 | Common | Form 4 ↗ |
| Eugene Schneider | EVP, Chf Clinical Develop Ofcr | 2026-06-26 | D | 26,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Joseph Baroldi | EVP, Chief Business Officer | 2026-06-26 | A | 1,769 | 33 | 57,669 | Common | Form 4 ↗ |
| Joseph Baroldi | EVP, Chief Business Officer | 2026-06-26 | A | 3,866 | 57 | 219,511 | Common | Form 4 ↗ |
| Patrick O'Neil | EVP CLO & General Counsel | 2026-06-26 | D | 3,069 | 80 | 245,520 | Common | Form 4 ↗ |
| Allene M. Diaz | Director | 2026-07-01 | A | 2,301 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Spencer R. Berthelsen | Director | 2026-07-01 | A | 5,369 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Allene M. Diaz | Director | 2026-07-01 | A | 5,369 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Hayden | Director | 2026-07-01 | A | 2,301 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Hayden | Director | 2026-07-01 | A | 5,369 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Joseph Klein III | Director | 2026-07-01 | D | 99 | 79 | 7,866 | Common | Form 4 ↗ |
| Joan E. Herman | Director | 2026-07-01 | A | 5,369 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Joseph Klein III | Director | 2026-07-01 | A | 11,518 | 40 | 460,029 | Common | Form 4 ↗ |
| Michael Yang | Director | 2026-07-01 | A | 2,301 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Yang | Director | 2026-07-01 | A | 5,369 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Joseph Klein III | Director | 2026-07-01 | D | 11,419 | 79 | 902,551 | Common | Form 4 ↗ |
| Joseph Klein III | Director | 2026-07-01 | D | 11,518 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Joan E. Herman | Director | 2026-07-01 | A | 2,301 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Joseph Loscalzo | Director | 2026-07-01 | A | 2,301 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Joseph Klein III | Director | 2026-07-01 | A | 2,301 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Joseph Klein III | Director | 2026-07-01 | A | 5,369 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Spencer R. Berthelsen | Director | 2026-07-01 | A | 2,301 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Joseph Loscalzo | Director | 2026-07-01 | A | 5,369 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Allene M. Diaz | Director | 2026-07-07 | D | 10,111 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Allene M. Diaz | Director | 2026-07-07 | D | 10,111 | 85 | 863,637 | Common | Form 4 ↗ |
| C. Frank Bennett | EVP, Chief Scientific Officer | 2026-07-07 | D | 15,000 | 85 | 1,281,930 | Common | Form 4 ↗ |
| Allene M. Diaz | Director | 2026-07-07 | A | 10,111 | 47 | 476,329 | Common | Form 4 ↗ |
| C. Frank Bennett | EVP, Chief Scientific Officer | 2026-07-07 | D | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| C. Frank Bennett | EVP, Chief Scientific Officer | 2026-07-07 | D | 5,536 | 84 | 462,693 | Common | Form 4 ↗ |
| C. Frank Bennett | EVP, Chief Scientific Officer | 2026-07-07 | A | 15,000 | 0 | 0 | Common | Form 4 ↗ |
| Holly B. Kordasiewicz | EVP, Chief Development Officer | 2026-07-07 | D | 362 | 84 | 30,517 | Common | Form 4 ↗ |
| Spencer R. Berthelsen | Director | 2026-07-15 | D | 5,220 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Spencer R. Berthelsen | Director | 2026-07-15 | A | 5,220 | 0 | 0 | Common | Form 4 ↗ |
| Joan E. Herman | Director | 2026-07-15 | D | 5,220 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Joan E. Herman | Director | 2026-07-15 | A | 5,220 | 0 | 0 | Common | Form 4 ↗ |
| Peter N. Reikes | Director | 2026-07-15 | A | 3,399 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ludwig Hantson | Director | 2026-07-15 | A | 3,399 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Hayden | Director | 2026-07-30 | A | 15,000 | 53 | 800,700 | Common | Form 4 ↗ |
| Michael Hayden | Director | 2026-07-31 | A | 5,000 | 52 | 258,000 | Common | Form 4 ↗ |
| Brett P. Monia | Director | 2026-08-31 | A | 98 | 51 | 5,028 | Common | Form 4 ↗ |
| Brian Birchler | EVP, Corp and Development Ops | 2026-08-31 | A | 58 | 51 | 2,976 | Common | Form 4 ↗ |
| Patrick O'Neil | EVP CLO & General Counsel | 2026-08-31 | A | 63 | 51 | 3,232 | Common | Form 4 ↗ |
| C. Frank Bennett | EVP, Chief Scientific Officer | 2026-08-31 | A | 110 | 51 | 5,644 | Common | Form 4 ↗ |
| Eric Swayze | EVP Research | 2026-10-15 | D | 125 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Eric Swayze | EVP Research | 2026-10-15 | A | 125 | 0 | 0 | Common | Form 4 ↗ |
| Shannon L. Devers | EVP, Chief Human Resources Ofc | 2026-10-15 | D | 2,820 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Shannon L. Devers | EVP, Chief Human Resources Ofc | 2026-10-15 | A | 2,820 | 0 | 0 | Common | Form 4 ↗ |
| Eric Swayze | EVP Research | 2026-10-16 | D | 53 | 44 | 2,308 | Common | Form 4 ↗ |
| Shannon L. Devers | EVP, Chief Human Resources Ofc | 2026-10-16 | D | 1,357 | 44 | 59,082 | Common | Form 4 ↗ |
Sources (182 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Brett Monia. DEF 14A, filed 2026-04-23. Section “Summary Compensation Table” · page 69. As printed: 13,350,777. View filing ↗
- Section 01, Elizabeth Hougen. DEF 14A, filed 2026-04-23. Section “Summary Compensation Table”. As printed: 4,422,302. View filing ↗
- Section 01, Richard Geary. DEF 14A, filed 2026-04-23. Section “Summary Compensation Table”. As printed: 3,331,400. View filing ↗
- Section 01, Brian Birchler. DEF 14A, filed 2026-04-23. Section “Summary Compensation Table”. As printed: 3,245,054. View filing ↗
- Section 01, Eric Swayze. DEF 14A, filed 2026-04-23. Section “Summary Compensation Table”. As printed: 3,233,339. View filing ↗
- Section 01, Patrick O'Neil. DEF 14A, filed 2026-04-23. Section “Summary Compensation Table”. As printed: 3,210,608. View filing ↗
- Section 03, Elizabeth Hougen RSU. DEF 14A, filed 2026-04-23. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Brett Monia RSU. DEF 14A, filed 2026-04-23. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Elizabeth Hougen PSU. DEF 14A, filed 2026-04-23. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Richard Geary PSU. DEF 14A, filed 2026-04-23. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Richard Geary OPTION. DEF 14A, filed 2026-04-23. Section “Grants of Plan-Based Awards in Fiscal 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Patrick O'Neil PSU. DEF 14A, filed 2026-04-23. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Brian Birchler PSU. DEF 14A, filed 2026-04-23. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Eric Swayze RSU. DEF 14A, filed 2026-04-23. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Eric Swayze PSU. DEF 14A, filed 2026-04-23. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Patrick O'Neil RSU. DEF 14A, filed 2026-04-23. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Brian Birchler RSU. DEF 14A, filed 2026-04-23. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Brett Monia PSU. DEF 14A, filed 2026-04-23. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Richard Geary RSU. DEF 14A, filed 2026-04-23. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Patrick O'Neil OPTION. DEF 14A, filed 2026-04-23. Section “Grants of Plan-Based Awards in Fiscal 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Brett Monia OPTION. DEF 14A, filed 2026-04-23. Section “Grants of Plan-Based Awards in Fiscal 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Eric Swayze OPTION. DEF 14A, filed 2026-04-23. Section “Grants of Plan-Based Awards in Fiscal 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Brian Birchler OPTION. DEF 14A, filed 2026-04-23. Section “Grants of Plan-Based Awards in Fiscal 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Elizabeth Hougen OPTION. DEF 14A, filed 2026-04-23. Section “Grants of Plan-Based Awards in Fiscal 2025” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-04-23. Section “CEO Pay Ratio”. As printed: 44 : 1. View filing ↗
- Section 08, Joseph H. Wender. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 598,780. View filing ↗
- Section 08, Joseph Loscalzo. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 568,780. View filing ↗
- Section 08, Spencer R. Berthelsen. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 548,780. View filing ↗
- Section 08, Joseph Klein III. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 543,780. View filing ↗
- Section 08, Joan E. Herman. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 541,280. View filing ↗
- Section 08, B. Lynne Parshall. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 538,780. View filing ↗
- Section 08, Allene M. Diaz. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 531,280. View filing ↗
- Section 08, Michael Hayden. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 528,780. View filing ↗
- Section 08, Michael Yang. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 518,780. View filing ↗
- Section 08, Brett P. Monia. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Joseph Baroldi 2026-04-28. Form 4, filed 2026-04-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joseph Klein III 2026-05-01. Form 4, filed 2026-05-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joseph Klein III 2026-05-01. Form 4, filed 2026-05-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joseph Klein III 2026-05-01. Form 4, filed 2026-05-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joseph Klein III 2026-05-01. Form 4, filed 2026-05-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joseph Loscalzo 2026-05-04. Form 4, filed 2026-05-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joseph Loscalzo 2026-05-04. Form 4, filed 2026-05-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joseph Loscalzo 2026-05-04. Form 4, filed 2026-05-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joseph Loscalzo 2026-05-04. Form 4, filed 2026-05-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joseph Loscalzo 2026-05-04. Form 4, filed 2026-05-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joseph Loscalzo 2026-05-04. Form 4, filed 2026-05-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joseph Loscalzo 2026-05-04. Form 4, filed 2026-05-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joseph Loscalzo 2026-05-04. Form 4, filed 2026-05-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joseph Loscalzo 2026-05-04. Form 4, filed 2026-05-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joseph Loscalzo 2026-05-04. Form 4, filed 2026-05-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joseph Loscalzo 2026-05-04. Form 4, filed 2026-05-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joseph Loscalzo 2026-05-04. Form 4, filed 2026-05-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joseph Loscalzo 2026-05-04. Form 4, filed 2026-05-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joseph Loscalzo 2026-05-04. Form 4, filed 2026-05-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brett P. Monia 2026-05-13. Form 4, filed 2026-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brett P. Monia 2026-05-13. Form 4, filed 2026-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brett P. Monia 2026-05-13. Form 4, filed 2026-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brett P. Monia 2026-05-14. Form 4, filed 2026-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brett P. Monia 2026-05-14. Form 4, filed 2026-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brett P. Monia 2026-05-14. Form 4, filed 2026-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Spencer R. Berthelsen 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Spencer R. Berthelsen 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Spencer R. Berthelsen 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ludwig Hantson 2026-06-04. Form 4, filed 2026-06-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Peter N. Reikes 2026-06-04. Form 4, filed 2026-06-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Holly B. Kordasiewicz 2026-06-12. Form 4, filed 2026-06-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Holly B. Kordasiewicz 2026-06-12. Form 4, filed 2026-06-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Holly B. Kordasiewicz 2026-06-12. Form 4, filed 2026-06-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Holly B. Kordasiewicz 2026-06-12. Form 4, filed 2026-06-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Holly B. Kordasiewicz 2026-06-12. Form 4, filed 2026-06-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Holly B. Kordasiewicz 2026-06-12. Form 4, filed 2026-06-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Holly B. Kordasiewicz 2026-06-12. Form 4, filed 2026-06-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Holly B. Kordasiewicz 2026-06-12. Form 4, filed 2026-06-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Holly B. Kordasiewicz 2026-06-12. Form 4, filed 2026-06-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Holly B. Kordasiewicz 2026-06-12. Form 4, filed 2026-06-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Spencer R. Berthelsen 2026-06-15. Form 4, filed 2026-06-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Spencer R. Berthelsen 2026-06-15. Form 4, filed 2026-06-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Spencer R. Berthelsen 2026-06-15. Form 4, filed 2026-06-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brett P. Monia 2026-06-24. Form 4, filed 2026-06-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brett P. Monia 2026-06-24. Form 4, filed 2026-06-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brett P. Monia 2026-06-24. Form 4, filed 2026-06-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brett P. Monia 2026-06-25. Form 4, filed 2026-06-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Eric Swayze 2026-06-25. Form 4, filed 2026-06-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brett P. Monia 2026-06-25. Form 4, filed 2026-06-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brett P. Monia 2026-06-25. Form 4, filed 2026-06-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joseph Baroldi 2026-06-26. Form 4, filed 2026-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brett P. Monia 2026-06-26. Form 4, filed 2026-06-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brett P. Monia 2026-06-26. Form 4, filed 2026-06-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brett P. Monia 2026-06-26. Form 4, filed 2026-06-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Eugene Schneider 2026-06-26. Form 4, filed 2026-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Eugene Schneider 2026-06-26. Form 4, filed 2026-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joseph Baroldi 2026-06-26. Form 4, filed 2026-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joseph Baroldi 2026-06-26. Form 4, filed 2026-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Eugene Schneider 2026-06-26. Form 4, filed 2026-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joseph Baroldi 2026-06-26. Form 4, filed 2026-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joseph Baroldi 2026-06-26. Form 4, filed 2026-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Patrick O'Neil 2026-06-26. Form 4, filed 2026-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Allene M. Diaz 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Spencer R. Berthelsen 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Allene M. Diaz 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Hayden 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Hayden 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joseph Klein III 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joan E. Herman 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joseph Klein III 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Yang 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Yang 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joseph Klein III 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joseph Klein III 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joan E. Herman 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joseph Loscalzo 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joseph Klein III 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joseph Klein III 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Spencer R. Berthelsen 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joseph Loscalzo 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Allene M. Diaz 2026-07-07. Form 4, filed 2026-07-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Allene M. Diaz 2026-07-07. Form 4, filed 2026-07-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, C. Frank Bennett 2026-07-07. Form 4, filed 2026-07-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Allene M. Diaz 2026-07-07. Form 4, filed 2026-07-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, C. Frank Bennett 2026-07-07. Form 4, filed 2026-07-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, C. Frank Bennett 2026-07-07. Form 4, filed 2026-07-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, C. Frank Bennett 2026-07-07. Form 4, filed 2026-07-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Holly B. Kordasiewicz 2026-07-07. Form 4, filed 2026-07-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Spencer R. Berthelsen 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Spencer R. Berthelsen 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joan E. Herman 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joan E. Herman 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Peter N. Reikes 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ludwig Hantson 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Hayden 2026-07-30. Form 4, filed 2026-07-31. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Hayden 2026-07-31. Form 4, filed 2026-07-31. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brett P. Monia 2026-08-31. Form 4, filed 2026-09-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian Birchler 2026-08-31. Form 4, filed 2026-09-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Patrick O'Neil 2026-08-31. Form 4, filed 2026-09-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, C. Frank Bennett 2026-08-31. Form 4, filed 2026-09-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Eric Swayze 2026-10-15. Form 4, filed 2026-10-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Eric Swayze 2026-10-15. Form 4, filed 2026-10-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Shannon L. Devers 2026-10-15. Form 4, filed 2026-10-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Shannon L. Devers 2026-10-15. Form 4, filed 2026-10-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Eric Swayze 2026-10-16. Form 4, filed 2026-10-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Shannon L. Devers 2026-10-16. Form 4, filed 2026-10-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-08. Item 5.07 · say-on-pay result. As reported: 96.38% (votes for as printed: 135,537,973). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-10. Item 5.07 · say-on-pay result. As reported: 95.78% (votes for as printed: 132,567,606). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-10. Item 5.07 · say-on-pay result. As reported: 96.57% (votes for as printed: 118,899,475). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 880,000 + equity 1,876,383 + all other 0 = 2,756,383, summed across the director compensation table rows.
- Exelixis, Section 10b CEO total. DEF 14A, filed 2026-04-15. CEO total compensation as printed in Exelixis's own proxy. As printed: 33,239,183. View filing ↗
- Incyte Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Incyte Corporation's own proxy. As printed: 32,085,952. View filing ↗
- PTC Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-20. CEO total compensation as printed in PTC Therapeutics's own proxy. As printed: 23,266,326. View filing ↗
- Halozyme Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-03-23. CEO total compensation as printed in Halozyme Therapeutics's own proxy. As printed: 23,166,223. View filing ↗
- BioMarin Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in BioMarin Pharmaceuticals's own proxy. As printed: 21,927,563. View filing ↗
- Jazz Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-06-08. CEO total compensation as printed in Jazz Pharmaceuticals's own proxy. As printed: 19,151,558. View filing ↗
- United Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in United Therapeutics's own proxy. As printed: 18,038,972. View filing ↗
- Exact Sciences Corp, Section 10b CEO total. DEF 14A, filed 2025-04-29. CEO total compensation as printed in Exact Sciences Corp's own proxy. As printed: 15,539,378. View filing ↗
- Corcept Therapeutics Inc., Section 10b CEO total. DEF 14A, filed 2026-04-17. CEO total compensation as printed in Corcept Therapeutics Inc.'s own proxy. As printed: 15,303,551. View filing ↗
- Insmed, Section 10b CEO total. DEF 14A, filed 2026-04-01. CEO total compensation as printed in Insmed's own proxy. As printed: 14,467,393. View filing ↗
- Blueprint Medicines Corp, Section 10b CEO total. DEF 14A, filed 2025-04-24. CEO total compensation as printed in Blueprint Medicines Corp's own proxy. As printed: 13,477,004. View filing ↗
- Neurocrine Biosciences, Section 10b CEO total. DEF 14A, filed 2026-04-15. CEO total compensation as printed in Neurocrine Biosciences's own proxy. As printed: 13,448,935. View filing ↗
- Ionis Pharmaceuticals Inc (subject), Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Ionis Pharmaceuticals Inc's own proxy. As printed: 13,350,777. View filing ↗
- BioCryst Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in BioCryst Pharmaceuticals, Inc.'s own proxy. As printed: 12,951,082. View filing ↗
- Ultragenyx Pharmaceutical, Section 10b CEO total. DEF 14A, filed 2026-03-27. CEO total compensation as printed in Ultragenyx Pharmaceutical's own proxy. As printed: 11,405,535. View filing ↗
- Apellis Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2025-04-23. CEO total compensation as printed in Apellis Pharmaceuticals's own proxy. As printed: 10,957,451. View filing ↗
- Axsome Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Axsome Therapeutics, Inc.'s own proxy. As printed: 10,283,492. View filing ↗
- Amicus Therapeutics, Section 10b CEO total. DEF 14A, filed 2025-04-24. CEO total compensation as printed in Amicus Therapeutics's own proxy. As printed: 8,526,943. View filing ↗
- Acadia Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Acadia Pharmaceuticals's own proxy. As printed: 8,256,518. View filing ↗
- Alkermes, Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in Alkermes's own proxy. As printed: 7,915,081. View filing ↗
- Sarepta Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Sarepta Therapeutics's own proxy. As printed: 7,840,666. View filing ↗
- Section 10a, Acadia Pharmaceuticals reciprocity. DEF 14A. Acadia Pharmaceuticals names Ionis Pharmaceuticals Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Amicus Therapeutics reciprocity. DEF 14A. Amicus Therapeutics names Ionis Pharmaceuticals Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Apellis Pharmaceuticals reciprocity. DEF 14A. Apellis Pharmaceuticals names Ionis Pharmaceuticals Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, BioMarin Pharmaceuticals reciprocity. DEF 14A. BioMarin Pharmaceuticals names Ionis Pharmaceuticals Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Exelixis reciprocity. DEF 14A. Exelixis names Ionis Pharmaceuticals Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Halozyme Therapeutics reciprocity. DEF 14A. Halozyme Therapeutics names Ionis Pharmaceuticals Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, PTC Therapeutics reciprocity. DEF 14A. PTC Therapeutics names Ionis Pharmaceuticals Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Sarepta Therapeutics reciprocity. DEF 14A. Sarepta Therapeutics names Ionis Pharmaceuticals Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Ultragenyx Pharmaceutical reciprocity. DEF 14A. Ultragenyx Pharmaceutical names Ionis Pharmaceuticals Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, United Therapeutics reciprocity. DEF 14A. United Therapeutics names Ionis Pharmaceuticals Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Neurocrine Biosciences reciprocity. DEF 14A. Neurocrine Biosciences names Ionis Pharmaceuticals Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Incyte Corporation reciprocity. DEF 14A. Incyte Corporation names Ionis Pharmaceuticals Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Blueprint Medicines Corp reciprocity. DEF 14A. Blueprint Medicines Corp names Ionis Pharmaceuticals Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Insmed reciprocity. DEF 14A. Insmed names Ionis Pharmaceuticals Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗